Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri, Gustavo Aroca et autres
Gabon, de, ar, es, co, nl, pe, mx, gb, us, be, pa (code pays fourni par la source)
176 citations
The Lancet Infectious Diseases